Market Value253,799,000
Total Holdings21
File Date2013-08-14
Original Filing (Click here)

All hedge funds or institutions that manage over $100M are required by the SEC to file quarterly reports on their holdings. These reports are called 13F reports. However, the filings are required the following quarter from the reporting period, which means that by the time the filing is made (and we see them), the information could be five months old.

For funds with long term positions that make few trades, the holdings might closely resemble their current holdings, even after several months. However, for funds that have high turnover, the holdings data we see might differ significantly from their current holdings. Institutions are required to report CALL and PUT options, and those positions are identified in the table. However, they are not required to report short positions.

Click the link icon to see the full transaction history.

Upgrade to unlock premium data and export to Excel .

Security Imputed
Share Price
Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
(USD x1000)
Current Value
(USD x1000)
Change
(Percent)
02318X100 / Ambit Biosciences Corp
BMRN / BioMarin Pharmaceutical Inc.
CORSICANTO LTD / NOTE 3.50% 1/15/32 (220480AC1)
CYCC / Cyclacel Pharmaceuticals, Inc.
DNDN /
24823QAC1 / Dendreon Corp Bond
ASRT / Assertio Holdings, Inc.
ECYT / Endocyte, Inc.
INTERMUNE INC / NOTE 2.50% 9/15/18 (45884XAE3)
MNKD / MannKind Corporation
MANNKIND CORP / NOTE 3.750% 12/15/13 (56400PAA0)
NAVB / Navidea Biopharmaceuticals, Inc.
NKTR / Nektar Therapeutics
ACHV / Achieve Life Sciences, Inc.
68375NAA1 / Opko Health, Inc. Bond
69329YAE4 / PDL BioPharma, Inc. Bond 2.875%
PACIRA PHARMACEUTICALS INC / NOTE 3.25% 2/1/19 (695127AA8)
RMTI / Rockwell Medical, Inc.
SLXP / Salix Therapeuticals, Inc.
SAVIENT PHARMACEUTICALS INC / NOTE 4.750% 2/1/18 (80517QAA8)
868459AA6 / Supernus Pharmaceuticals, Inc. Bond